Retrieve available abstracts of 65 articles: HTML format
Single Articles
June 2025
NIERENGARTEN MB Acute toxicity of prostate cancer radiotherapy associated with late toxicity:
Acute toxicity following prostate cancer radiotherapy was statistically and
significantly associated with late toxicity in patient-reported quality-of-life
metrics.
Cancer. 2025;131:e35886. PubMed
GINSBURG KB, Sessine MS, Bock CH, Goodman M, et al Factors associated with switching from active surveillance to treatment in men
with low-risk prostate cancer: A population-based study.
Cancer. 2025;131:e35909. PubMedAbstract available
May 2025
GARG SK, Kohli K, Garg IK, Garg YK, et al Disparities in receipt of palliative-intent treatment among disaggregated
Hispanic populations with breast, lung, and prostate cancer in the United States.
Cancer. 2025;131:e35903. PubMedAbstract available
April 2025
LAWRENCE WR, Freedman ND, McGee-Avila JK, Hong HG, et al Contemporary neighborhood redlining and racial mortgage lending bias and
disparities in prostate cancer survival.
Cancer. 2025;131:e35850. PubMedAbstract available
FUKUOKAYA W, Mori K, Yanagisawa T, Urabe F, et al Tumor burden and heterogenous treatment effect of apalutamide in metastatic
castration-sensitive prostate cancer.
Cancer. 2025;131:e35819. PubMedAbstract available
March 2025
SEBASTIAN NT, Patil D, Patel PR, Jani AB, et al Utilization, health care expenditures, and patient costs of definitive treatment
modalities for localized prostate cancer in the United States.
Cancer. 2025;131:e35795. PubMedAbstract available
NIERENGARTEN MB Higher rates of long-term complications after prostate cancer treatment.
Cancer. 2025;131:e35761. PubMed
NIERENGARTEN MB Reduced long-term side effects with MRI-guided radiotherapy in prostate cancer.
Cancer. 2025;131:e35762. PubMed
February 2025
NIERENGARTEN MB Healthy diet may reduce the risk of low-grade prostate cancer progressing to a
higher grade.
Cancer. 2025;131:e35740. PubMed
January 2025
CASTANEDA P, Kuhlmann PK, Ithisuphalap J, Howard LE, et al Alternate definitions of adverse pathology to predict a very high risk of
metastasis in men with intermediate- and low-risk prostate cancer.
Cancer. 2025;131:e35684. PubMedAbstract available
NORIEGA ESQUIVES BS, Moreno PI, Munoz E, Lad TE, et al Effects of a culturally tailored patient navigation program on unmet supportive
care needs in Hispanic/Latino cancer survivors: A randomized controlled trial.
Cancer. 2025;131:e35626. PubMedAbstract available
December 2024
MUKAND NH, Chirikova E, Lichtensztajn D, Negoita S, et al Assessing sociodemographic and regional disparities in Oncotype DX Genomic
Prostate Score uptake.
Cancer. 2024;130:4298-4305. PubMedAbstract available
SAYAN M, Chen MH, Wu J, Leeman JE, et al Biochemical response to neoadjuvant androgen deprivation therapy before radiation
therapy and the risk of death in patients with unfavorable-risk prostate cancer:
A secondary analysis of a randomized clinical trial.
Cancer. 2024 Dec 4. doi: 10.1002/cncr.35674. PubMedAbstract available
BRYCE AH, Agarwal N, Beltran H, Hussain MH, et al Implementing evidence-based strategies for men with biochemically recurrent and
advanced prostate cancer: Consensus recommendations from the US Prostate Cancer
Conference 2024.
Cancer. 2024 Dec 1. doi: 10.1002/cncr.35612. PubMedAbstract available
November 2024
SRIVASTAVA A, Liu X, Maganty A, Kaufman SR, et al Commercial prices and their influence on urology practices: Prostate cancer care
among men with Medicare.
Cancer. 2024 Nov 5. doi: 10.1002/cncr.35633. PubMedAbstract available
SOERENSEN SJC, Lim DS, Montez-Rath ME, Chertow GM, et al Pesticides and prostate cancer incidence and mortality: An environment-wide
association study.
Cancer. 2024 Nov 4. doi: 10.1002/cncr.35572. PubMedAbstract available
October 2024
NIERENGARTEN MB Androgen receptor signaling inhibitors linked to increased risk of cardiovascular
adverse events in prostate cancer.
Cancer. 2024;130:3399. PubMed
MOUSA A, Nguyen DD, Lalani AK, Satkunasivam R, et al Metabolic, cardiac, and bone health testing in patients with prostate cancer on
androgen-deprivation therapy: A population-based assessment of adherence to
therapeutic monitoring guidelines.
Cancer. 2024 Oct 13. doi: 10.1002/cncr.35606. PubMedAbstract available
CIRULLI GO, Davis M, Stephens A, Chiarelli G, et al Midlife baseline prostate-specific antigen, velocity, and doubling time
association with lethal prostate cancer and mortality.
Cancer. 2024 Oct 8. doi: 10.1002/cncr.35563. PubMedAbstract available
September 2024
ZHENG R, Daniels JP, Moreira DM, Eslamimehr S, et al Does insulin resistance predict prostate cancer? Results from the Reduction by
Dutasteride of Prostate Cancer (REDUCE) Trial.
Cancer. 2024 Sep 27. doi: 10.1002/cncr.35568. PubMedAbstract available
KILBRIDGE KL, Patil D, Filson CP, Shelton JW, et al Tailoring language for genitourinary function in patients with newly diagnosed
prostate cancer to facilitate discussions in diverse populations and overcome
health literacy barriers.
Cancer. 2024 Sep 10. doi: 10.1002/cncr.35498. PubMedAbstract available
Addition of apalutamide to ADT after radical prostatectomy offers encouraging
results.
Cancer. 2024;130:2896. PubMed
NIERENGARTEN MB Optimal timing of radiotherapy after radical prostatectomy points to salvage
radiotherapy for PSA failure.
Cancer. 2024;130:2895. PubMed
August 2024
BEATRICI E, Paciotti M, Nguyen DD, Filipas DK, et al Estimating the impact of enhanced care at minority-serving hospitals on
disparities in the treatment of breast, prostate, lung, and colon cancers.
Cancer. 2024;130:2770-2781. PubMedAbstract available
July 2024
MORGANS AK Optimizing assessments of quality of life in contemporary prostate cancer
clinical trials.
Cancer. 2024 Jul 27. doi: 10.1002/cncr.35485. PubMed
LEE YHA, Kai Chan JS, Leung CH, Liu AQ, et al Comparison of infection risk between enzalutamide and abiraterone in patients
with prostate cancer.
Cancer. 2024 Jul 21. doi: 10.1002/cncr.35472. PubMedAbstract available
MEAGHER M, Morgan K, Deshler L, Riviere P, et al Prostate cancer in transgender women: A propensity score-matched analysis of
disease severity and survival.
Cancer. 2024 Jul 21. doi: 10.1002/cncr.35469. PubMedAbstract available
SANYAL C, Ragavan MV Beyond the PSA: The hidden costs of screening in prostate cancer.
Cancer. 2024 Jul 16. doi: 10.1002/cncr.35474. PubMed
NIERENGARTEN MB Novel hormone is safe and effective in men receiving radiotherapy for prostate
cancer.
Cancer. 2024;130:2408. PubMed
SRIVASTAVA A, Tilea A, Kim DD, Dalton VK, et al Out-of-pocket costs for diagnostic testing following abnormal prostate cancer
screening among privately insured men.
Cancer. 2024 Jul 15. doi: 10.1002/cncr.35392. PubMedAbstract available
GONG J, Janes JL, Trustram Eve C, Stock S, et al Epidemiology, treatment patterns, and clinical outcomes in de novo
oligometastatic hormone-sensitive prostate cancer.
Cancer. 2024 Jul 1. doi: 10.1002/cncr.35466. PubMedAbstract available
June 2024
MORRIS MJ, de Bono J, Nagarajah J, Sartor O, et al Correlation analyses of radiographic progression-free survival with clinical and
health-related quality of life outcomes in metastatic castration-resistant
prostate cancer: Analysis of the phase 3 VISION trial.
Cancer. 2024 Jun 21. doi: 10.1002/cncr.35438. PubMedAbstract available
BASARIA S, Taplin ME, McDonnell M, Simonson DC, et al Insulin resistance during androgen deprivation therapy in men with prostate
cancer.
Cancer. 2024 Jun 16. doi: 10.1002/cncr.35443. PubMedAbstract available
PAGADALA MS, Lui A, Lynch J, Karunamuni R, et al Healthy lifestyle and prostate cancer risk in the Million Veteran Program.
Cancer. 2024 Jun 12. doi: 10.1002/cncr.35434. PubMedAbstract available
LABBAN M, Stone BV, Steele GL, Salinas KE, et al A qualitative approach to understanding the drivers of unequal receipt of
definitive therapy for Black men with prostate cancer in Massachusetts.
Cancer. 2024 Jun 4. doi: 10.1002/cncr.35366. PubMedAbstract available
May 2024
TINSLEY SA, Finati M, Stephens A, Chiarelli G, et al Race has no impact on prostate cancer-specific mortality, when comparing patients
with similar risk of other-cause mortality: An analysis of a population-based
cohort.
Cancer. 2024 May 28. doi: 10.1002/cncr.35386. PubMedAbstract available
April 2024
BENADADA F, Saad F, Delouya G, Taussky D, et al Charles Brenton Huggins: A historical review of the Nobel laureate's pioneering
discoveries.
Cancer. 2024;130:1019-1024. PubMedAbstract available
March 2024
SOLANKI AJ, Kamrava M, Posadas EM, Freedland SJ, et al A practical guide for assessing and managing cardiovascular risk during
androgen-deprivation therapy in patients with prostate cancer.
Cancer. 2024 Mar 26. doi: 10.1002/cncr.35285. PubMedAbstract available
PEPPONE LJ, Kleckner AS, Fung C, Puzas JE, et al High-dose vitamin D to attenuate bone loss in patients with prostate cancer on
androgen deprivation therapy: A phase 2 RCT.
Cancer. 2024 Mar 23. doi: 10.1002/cncr.35275. PubMedAbstract available
LIM FAT G, Alibhai S Effect of hormonal therapies for prostate cancer on cognition: The ongoing search
for clarity.
Cancer. 2024 Mar 16. doi: 10.1002/cncr.35283. PubMed
WALBURN T, Chen MH, Loffredo M, McMahon E, et al Secondary analysis of late major gastrointestinal and genitourinary toxicities in
unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a
randomized trial.
Cancer. 2024 Mar 1. doi: 10.1002/cncr.35274. PubMedAbstract available
February 2024
FARAJ KS, Kaufman SR, Oerline M, Herrel LA, et al The 340B Program and oral specialty drugs for advanced prostate cancer.
Cancer. 2024 Feb 23. doi: 10.1002/cncr.35262. PubMedAbstract available
RUAN Y, Heer E, Warkentin MT, Jarada TN, et al The association between neighborhood-level income and cancer stage at diagnosis
and survival in Alberta.
Cancer. 2024;130:563-575. PubMedAbstract available
WRIGHT JL, Schenk JM, Gulati R, Beatty SJ, et al The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial
of diet and exercise in overweight and obese men on active surveillance.
Cancer. 2024 Feb 14. doi: 10.1002/cncr.35241. PubMedAbstract available
LOEB S, Hua Q, Bauer SR, Kenfield SA, et al Plant-based diet associated with better quality of life in prostate cancer
survivors.
Cancer. 2024 Feb 13. doi: 10.1002/cncr.35172. PubMedAbstract available
HIGANO CS, Dizdarevic S, Logue J, Richardson T, et al Safety and effectiveness of the radium-223-taxane treatment sequence in patients
with metastatic castration-resistant prostate cancer in a global observational
study (REASSURE).
Cancer. 2024 Feb 10. doi: 10.1002/cncr.35221. PubMedAbstract available
DORFF TB, Bryce AH Challenges in clinical trials for high-risk but curable prostate cancer.
Cancer. 2024 Feb 10. doi: 10.1002/cncr.35245. PubMed
BOUE A, Joly F, Lequesne J, Lange M, et al Does hormone therapy impact cognition in patients with prostate cancer? A
systematic review and meta-analysis.
Cancer. 2024 Feb 2. doi: 10.1002/cncr.35210. PubMedAbstract available
January 2024
BYRD DA, Zouiouich S, Karwa S, Li XS, et al Associations of serum trimethylamine N-oxide and its precursors with colorectal
cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial
Cohort.
Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219. PubMedAbstract available
BRAUN AE, Chan JM, Neuhaus J, Cowan JE, et al The impact of genomic biomarkers on a clinical risk prediction model for
upgrading/upstaging among men with favorable-risk prostate cancer.
Cancer. 2024 Jan 27. doi: 10.1002/cncr.35215. PubMedAbstract available
XU J, Bock CH, Janisse J, Woo J, et al Determinants of active surveillance uptake in a diverse population-based cohort
of men with low-risk prostate cancer: The Treatment Options in Prostate Cancer
Study (TOPCS).
Cancer. 2024 Jan 22. doi: 10.1002/cncr.35190. PubMedAbstract available
MCKAY RR, Xie W, Yang X, Acosta A, et al Postradical prostatectomy prostate-specific antigen outcomes after 6 versus
18 months of perioperative androgen-deprivation therapy in men with localized,
unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of
a randomized ph
Cancer. 2024 Jan 1. doi: 10.1002/cncr.35170. PubMedAbstract available
December 2023
FARAJ KS, Kaufman SR, Herrel LA, Maganty A, et al Urologist practice divestment from radiation vault ownership and treatment
patterns for prostate cancer.
Cancer. 2023 Dec 26. doi: 10.1002/cncr.35168. PubMedAbstract available
FDA approves new combined treatment for advanced prostate cancer.
Cancer. 2023;129:3841-3842. PubMed
KARAN D, Wick J, Dubey S, Kumar-Sinha C, et al Reply to "Contextualizing racial associations in prostate cancer to expose
structural causes".
Cancer. 2023 Dec 11. doi: 10.1002/cncr.35167. PubMed
ROLLIN FG, Olsen E, George M Contextualizing racial associations in prostate cancer to expose structural
causes.
Cancer. 2023 Dec 11. doi: 10.1002/cncr.35157. PubMed
GAFFNEY CD, Tin AL, Fainberg J, Fine S, et al The oncologic risk of magnetic resonance imaging-targeted and systematic cores in
patients treated with radical prostatectomy.
Cancer. 2023;129:3790-3796. PubMedAbstract available
November 2023
YANG K, Doege D, Thong MSY, Koch-Gallenkamp L, et al Diabetes mellitus in long-term survivors with colorectal, breast, or prostate
cancer: Prevalence and prognosis. A population-based study.
Cancer. 2023 Nov 23. doi: 10.1002/cncr.35133. PubMedAbstract available
NIERENGARTEN MB Targeting metabolic abnormality for advanced prostate cancer: The prodrug
Platin-L effectively targets the metabolic abnormality needed to make this cancer
sensitive to cisplatin.
Cancer. 2023;129:3516. PubMed
BRAWLEY OW, Ramalingam R The enigma of race and prostate cancer.
Cancer. 2023 Nov 6. doi: 10.1002/cncr.35032. PubMed
LEE KM, Bryant AK, Lynch JA, Robison B, et al Association between prediagnostic PSA and prostate cancer probability in Black
and non-Hispanic White men.
Cancer. 2023 Nov 6. doi: 10.1002/cncr.34979. PubMedAbstract available
October 2023
NIERENGARTEN MB Genomics likely are not the main driver in advanced prostate cancer overall
survival rate disparities.
Cancer. 2023;129:3192. PubMed
LEEMAN JE, Shin KY, Chen YH, Mak RH, et al Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial
or computed tomography-guided non-adaptive prostate stereotactic body
radiotherapy: A systematic review and meta-analysis.
Cancer. 2023;129:3044-3052. PubMedAbstract available
September 2023
KARAN D, Wick J, Dubey S, Kumar-Sinha C, et al Racial differences in serum chemokines in prostate cancer patients.
Cancer. 2023 Sep 12. doi: 10.1002/cncr.35012. PubMedAbstract available
August 2023
ISLAMI F, Wiese D, Marlow EC, Kratzer TB, et al Progress in reducing cancer mortality in the United States by congressional
district, 1996-2003 to 2012-2020.
Cancer. 2023;129:2522-2531. PubMedAbstract available